<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595581</url>
  </required_header>
  <id_info>
    <org_study_id>HS-11-00649</org_study_id>
    <nct_id>NCT01595581</nct_id>
  </id_info>
  <brief_title>Testosterone Administration and ACL Reconstruction in Men</brief_title>
  <acronym>TACL</acronym>
  <official_title>The Effects of Acute Testosterone Administration in Men on Muscle Mass, Strength, and Physical Function Following ACL Reconstructive Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oregon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to test whether taking testosterone can prevent loss of muscle mass&#xD;
      and strength due to anterior cruciate ligament (ACL) reconstructive surgery. Testosterone is&#xD;
      the principal male sex hormone and an anabolic (muscle promoting) steroid. It is essential&#xD;
      for the development of male reproductive tissues and promotes increased muscle, bone mass,&#xD;
      and the growth of body hair.&#xD;
&#xD;
      The investigators hope to learn whether testosterone given before and after ACL&#xD;
      reconstructive surgery will increase muscle mass and strength and potentially improve&#xD;
      recovery time following surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overall Objective: The overall objective of this study is to determine if 8 weeks of&#xD;
      testosterone first administered 2 weeks prior to surgery, can improve the outcome of anterior&#xD;
      cruciate ligament (ACL) reconstruction.&#xD;
&#xD;
      Overall Hypothesis: Standard-of-care rehabilitation with the addition of testosterone&#xD;
      administration will augment muscle mass, strength, and physical function following ACL&#xD;
      reconstructive surgery compared to standard rehabilitation alone.&#xD;
&#xD;
      Significance: Muscle mass and strength are greatly reduced following ACL surgery. The&#xD;
      investigators hypothesize that administration of testosterone will minimize these reductions&#xD;
      or potentially increase muscle mass and strength. In doing so, testosterone may hasten a&#xD;
      patient's return to physical activity. If testosterone improves recovery after ACL surgery,&#xD;
      the same treatment may be used for other injuries that involve trauma and muscle atrophy.&#xD;
      Furthermore, this study will examine the effect of trauma with or without testosterone on&#xD;
      myogenic regulators in muscle tissue taken during ACL surgery-providing possible mechanistic&#xD;
      insights for the clinical outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in lean mass</measure>
    <time_frame>6, 12 weeks</time_frame>
    <description>Relative changes in lean mass from 2 weeks prior to surgery to multiple time points (1 day prior to surgery, and 6 and 12 weeks following surgery) between the two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>KOOS scores</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in KOOS score from 2 weeks prior to surgery to 12 weeks following surgery between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strength</measure>
    <time_frame>6, 12 weeks</time_frame>
    <description>Changes in muscle strength and knee stability from the start of rehabilitation to 6 and 12 weeks following surgery between the two groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Muscle Atrophy</condition>
  <condition>ACL Reconstruction</condition>
  <condition>Trauma</condition>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Testosterone, standard-of-care rehabilitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-of-care rehabilitation, Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>8 weeks supraphysiologic dose testosterone enanthate</description>
    <arm_group_label>Testosterone, standard-of-care rehabilitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo for 8 weeks</description>
    <arm_group_label>Standard-of-care rehabilitation, Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A complete ACL tear as visualized on MRI&#xD;
&#xD;
          -  The ACL injury can be either &quot;isolated&quot; or combined with one or several of the&#xD;
             following injuries visualized on MRI and/or arthroscopy:&#xD;
&#xD;
          -  a meniscus tear that is either left untreated or treated with a partial resection&#xD;
&#xD;
          -  a small, stable meniscus tear treated with fixation, but with the fixation not&#xD;
             interfering with the rehabilitation protocol&#xD;
&#xD;
          -  cartilage changes verified on MRI with an arthroscopically determined intact surface.&#xD;
&#xD;
          -  A radiographic examination with normal joint status or combined with either one of the&#xD;
             following findings:&#xD;
&#xD;
          -  a small-avulsed fragment located laterally, usually described as a Segond fracture,&#xD;
             JSN grade 1 or osteophytes grade 1 as determined by the OARSI atlas15&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous major knee injury or knee surgery&#xD;
&#xD;
          -  Associated posterior cruciate ligament (PCL) or medical collateral ligament (MCL)&#xD;
             injury grade III&#xD;
&#xD;
          -  Concomitant severe injury to contra-lateral knee&#xD;
&#xD;
          -  Injury to the lateral/posterolateral ligament complex with significantly increased&#xD;
             laxity&#xD;
&#xD;
          -  Unstable longitudinal meniscus tear that requires repair and where the following&#xD;
             postoperative treatment (we.e. bracing and limited range of motion) interferes with&#xD;
             the rehabilitation protocol&#xD;
&#xD;
          -  Bi-compartmental extensive meniscus resections&#xD;
&#xD;
          -  Cartilage injury representing a full thickness loss down to bone&#xD;
&#xD;
          -  Total rupture of MCL/LCL as visualized on MRI.&#xD;
&#xD;
          -  History of deep vein thrombosis (DVT) or a disorder of the coagulative system&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Prior or current use of anabolic steroids&#xD;
&#xD;
          -  General systemic disease affecting physical function&#xD;
&#xD;
          -  Chromosomal disorders&#xD;
&#xD;
          -  Medications that interfere with testosterone production or function, including but not&#xD;
             limited to 5Î±-reductase inhibitors&#xD;
&#xD;
          -  Any other condition or treatment interfering with the completion of the trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Todd Schroeder, PhD</last_name>
    <phone>(323) 442-2498</phone>
    <email>eschroed@usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brian Wu</last_name>
    <phone>(323) 442-2180</phone>
    <email>brianwwu@usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Schroeder, PhD</last_name>
      <phone>323-442-2498</phone>
      <email>eschroed@usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brian Wu</last_name>
      <phone>(323) 442 2180</phone>
      <email>brianwwu@usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Todd Schroeder, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>May 8, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Todd Schroeder</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Physical Therapy</investigator_title>
  </responsible_party>
  <keyword>Testosterone</keyword>
  <keyword>ACL Reconstruction</keyword>
  <keyword>Clinical outcomes</keyword>
  <keyword>Lean mass</keyword>
  <keyword>Strength</keyword>
  <keyword>Muscle atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 30, 2017</submitted>
    <returned>May 10, 2017</returned>
    <submitted>May 23, 2017</submitted>
    <returned>June 26, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

